NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia
Sign Up to like & getrecommendations! Published in 2021 at "Investigational New Drugs"
DOI: 10.1007/s10637-020-01028-8
Abstract: Chronic myeloid leukemia (CML) is successfully treated with BCR-ABL1 tyrosine kinase inhibitors, but a significant percentage of patients develop resistance. Insulin receptor substrate 1 (IRS1) has been shown to constitutively associate with BCR-ABL1, and IRS1-specific… read more here.
Keywords: igf1r irs1; irs1; bcr abl1; antineoplastic effects ... See more keywords